Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Repros Therapeutics Inc.)"
Count: 59
Selected: 0
| NCT ID | Title |
|---|
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | ||
| NCT02651688 | A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene | ||
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | ||
| NCT02301897 | A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | ||
| NCT02274181 | An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration | ||
| NCT02169804 | An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal | ||
| NCT02146391 | Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal | ||
| NCT02141061 | Comparison of Two Formulations of Proellex for Oral Administration | ||
| NCT02117830 | A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects | ||
| NCT01993225 | A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% | ||
| NCT01993212 | A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% | ||
| NCT01991327 | Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males | ||
| NCT01984398 | Comparison of Two Formulations of Androxal | ||
| NCT01962805 | Comparison of Two Formulations of Proellex for Vaginal Administration | ||
| NCT01961908 | Open-Label Extension Study to ZPE-202 | ||
| NCT01959685 | A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal | ||
| NCT01923870 | Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function | ||
| NCT01923857 | Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function | ||
| NCT01739621 | Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 | ||
| NCT01739595 | Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism | ||
| NCT01739582 | An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | ||
| NCT01728454 | Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis | ||
| NCT01631903 | Extension of Study ZPV-200 | ||
| NCT01619683 | Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism | ||
| NCT01534208 | Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | ||
| NCT01532414 | Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism | ||
| NCT01451424 | Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids | ||
| NCT01386606 | The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) | ||
| NCT01386567 | A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203 | ||
| NCT01270841 | Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism | ||
| NCT01191320 | Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus | ||
| NCT01187043 | Determination of the Lowest, Safe and Effective Dose of Proellex | ||
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | ||
| NCT01069094 | A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata | ||
| NCT01067807 | Proellex Pharmacokinetics Bridging Study | ||
| NCT01067365 | Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism | ||
| NCT00962637 | Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism | ||
| NCT00958893 | An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext | ||
| NCT00958412 | Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study | ||
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | ||
| NCT00882258 | Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids | ||
| NCT00881608 | Study to Evaluate Menses Induction in Women Administered Proellex | ||
| NCT00881062 | Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females | ||
| NCT00874302 | Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms | ||
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | ||
| NCT00787618 | Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females | ||
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | ||
| NCT00749879 | Crossover Study of the Safety and PK Properties of Proellex® | ||
| NCT00741468 | Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects | ||
| NCT00741273 | Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults |
